Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to move ahead follows talks with FDA suggesting existing data are sufficient for filing, despite failure of one of two pivotal trials.

You may also be interested in...



Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine

Company says it is the first to submit a therapeutic cancer vaccine application to FDA.

Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine

Company says it is the first to submit a therapeutic cancer vaccine application to FDA.

Intracel OncoVAX Phase III Will Follow Patients For Three Years

Firm says single pivotal trial of the autologous cancer vaccine can support a BLA for adjuvant treatment of Stage II colon cancer.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel